

Annual Flash Report (unaudited)

Fiscal Year ended March 31, 2015

Sales of Major Products

Supplemental Data

For information purpose only

		2015					Year ending
		Results		Increase/Decrease			March
							31,2016
		¥		¥			Forecast
Glactiv	Agent for type II diabetes	¥	308	¥	△ 49	△ 13.7 %	¥ 320
Opalmon	Circulatory system agent		248		△ 77	△ 23.6 %	225
Recalbon	Agent for osteoporosis		103		△ 8	△ 7.4 %	110
Emend/Proemend	Agent for Chemotherapy-induced nausea and vomiting		86		△ 2	△ 1.8 %	95
Onon	Agent for bronchial asthma and allergic rhinitis		102		△ 32	△ 23.9 %	90
Rivastach	Agent for Alzheimer's disease		68		+4	+6.0 %	85
Forxiga	Agent for type II diabetes		15		—	—	75
Orencia SC	Agent for rheumatoid arthritis		41		+33	+419.2 %	70
Onon dry syrup	Agent for pediatric bronchial asthma and allergic rhinitis		58		△ 11	△ 16.0 %	55
Foipan	Agent for chronic pancreatitis and postoperative reflux esophagitis		61		△ 19	△ 24.2 %	50
Onoact	Agent for tachyarrhythmia during and post operation		47		+3	+6.3 %	50
Staybla	Agent for overactive bladder (pollakiuria and urinary incontinence)		53		△ 12	△ 19.2 %	45
Kinedak	Agent for diabetic peripheral neuropathy		48		△ 26	△ 35.5 %	45
Opdivo	Agent for treatment of unresectable melanoma		25		—	—	35
Elaspol	Agent for acute lung injury associated with SIRS		27		△ 9	△ 24.1 %	20

Note: 1 Sales of products are shown in a gross sales basis.

2 Forxiga and Opdivo were launched in Fiscal year ended March 31, 2015 and year-on-year changes in value and percentage are therefore not available.